Fortvita Biologics (USA)Inc.
7
5
6
0
Key Highlights
Risk & Performance
Pipeline Risk Assessment
Pipeline Risk Assessment
Based on historical performance
Moderate Risk
Score: 45/100
0.0%
0 terminated/withdrawn out of 7 trials
0%
0 trials in Phase 3/4
0%
0 of 0 completed trials have results
Key Signals
Enrollment Performance
Analytics
Activity Timeline
Global Presence
Clinical Trials (7)
IBI3001 in Participants With Unresectable, Locally Advanced or Metastatic Solid Tumors
Role: lead
Study of IBI3020 Treatment in Participants With Late-Stage Solid Tumors
Role: lead
A Study of IBI3042 in Healthy Adult Participants
Role: lead
A Study of IBI3003 in Subjects With Relapsed or Refractory Multiple Myeloma
Role: lead
A First-in-human Study of IBI343 in Subjects With Locally Advanced Unresectable or Metastatic Solid Tumors
Role: collaborator
A Phase 1, Open-label, Multicenter, Dose Escalation Study of IBI363 (PD1-IL2m) in Subjects With Advanced Solid Malignancies or Lymphomas
Role: collaborator
A Study of IBI3032 in Healthy Participants
Role: lead
All 7 trials loaded